Processa rises on positive data from early-stage study on cancer treatment
11/06/2024 14:22
** Shares of drug developer Processa Pharmaceuticals
PCSA.O rise 12.7% to $1.78 premarket
** Co announces positive efficacy results from the
preliminary evaluation of the recently completed early-stage
study on its combination cancer treatment, NGC-Cap
** The treatment is a combination of PCSA's cancer therapy
candidate, PCS6422, with an approved chemotherapy drug,
capecitabine, which was tested in patients with stage three or
four stomach cancer
** Co says 8 out of 12 evaluable patients that were given
the treatment had progression free survival of about five to
eleven months
** The two dosage regimens tested in the study will be
further evaluated in a mid-stage study in breast cancer patients
to determine the optimal dosage for the treatment, co says
** Up to last close, stock down 76.4% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))